Lipocine names Grissinger to compensation committee

Q: What change did Lipocine Inc. (LPCN) disclose in this 8-K/A?

Lipocine Inc. disclosed that its Board appointed Michael Grissinger as a member of the Compensation Committee, supplementing his previously reported appointment to the Board.

Q: When was Michael Grissinger appointed to Lipocine’s Compensation Committee?

The Board of Directors of Lipocine Inc. appointed Michael Grissinger to the Compensation Committee on August 18, 2026, as disclosed in this amendment.

Q: How much additional compensation will Michael Grissinger receive for committee service at LPCN?

For serving on Lipocine’s Compensation Committee, Michael Grissinger is eligible to receive an additional $7,500 per year, on top of any other compensation for Board service.

Q: Why did Lipocine Inc. file this Form 8-K/A amendment?

The amendment was filed to specifically report Michael Grissinger’s appointment to the Compensation Committee of the Board, which was not included in the earlier report of his Board appointment.

Q: Who signed the Lipocine Inc. (LPCN) 8-K/A and in what capacity?

The amendment was signed by Mahesh V. Patel, who is identified as the company’s President and Chief Executive Officer, dated August 21, 2026.

Lipocine Inc. (LPCN) filed an amendment to report that its Board of Directors appointed Michael Grissinger to serve as a member of the Compensation Committee.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K/A

Rhea-AI Filing Summary

Lipocine Inc. (LPCN) filed an amendment to report that its Board of Directors appointed Michael Grissinger to serve as a member of the Compensation Committee. The Board made this committee appointment on August 18, 2026, following his earlier appointment to the Board reported on August 3, 2026.

For his additional duties on the Compensation Committee, Mr. Grissinger is eligible to receive an extra $7,500 per year in compensation. The report is signed by President and Chief Executive Officer Mahesh V. Patel on August 21, 2026.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Key Figures

Additional annual committee compensation: $7,500 per year Committee appointment date: August 18, 2026 Board appointment disclosure date: August 3, 2026 +1 more

4 metrics

Additional annual committee compensation $7,500 per year Amount Mr. Grissinger is eligible to receive for Compensation Committee service

Committee appointment date August 18, 2026 Date the Board appointed Mr. Grissinger to the Compensation Committee

Board appointment disclosure date August 3, 2026 Date referenced for prior report of Mr. Grissinger’s Board appointment

Signature date August 21, 2026 Date the report was signed by the President and CEO

Key Terms

Compensation Committee, Board of Directors, emerging growth company

3 terms

Compensation Committee financial

"appointed Michael Grissinger to serve as a member of the Compensation Committee"

A compensation committee is a group within a company's leadership responsible for setting and reviewing how much top executives and employees are paid, including salaries, bonuses, and benefits. It matters to investors because fair and effective pay decisions can influence a company's performance, leadership motivation, and overall governance, helping ensure that the company’s management is aligned with shareholders’ interests.

Board of Directors financial

"the Board of Directors (the “Board”) of the Company appointed"

The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.

emerging growth company regulatory

"405) or Rule 12b-2 of the Securities Exchange Act of 1934 ... Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What change did Lipocine Inc. (LPCN) disclose in this 8-K/A?

Lipocine Inc. disclosed that its Board appointed Michael Grissinger as a member of the Compensation Committee, supplementing his previously reported appointment to the Board.

When was Michael Grissinger appointed to Lipocine’s Compensation Committee?

The Board of Directors of Lipocine Inc. appointed Michael Grissinger to the Compensation Committee on August 18, 2026, as disclosed in this amendment.

How much additional compensation will Michael Grissinger receive for committee service at LPCN?

For serving on Lipocine’s Compensation Committee, Michael Grissinger is eligible to receive an additional $7,500 per year, on top of any other compensation for Board service.

Why did Lipocine Inc. file this Form 8-K/A amendment?

The amendment was filed to specifically report Michael Grissinger’s appointment to the Compensation Committee of the Board, which was not included in the earlier report of his Board appointment.

Who signed the Lipocine Inc. (LPCN) 8-K/A and in what capacity?

The amendment was signed by Mahesh V. Patel, who is identified as the company’s President and Chief Executive Officer, dated August 21, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 08/21/2026 - 04:30 PM EDT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K/A

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

August 3, 2026

LIPOCINE INC.

(Exact name of registrant as specified in its charter)

Commission File No. 001-36357

Delaware

99-0370688

(State or other jurisdiction

of incorporation)

(IRS Employer

Identification Number)

675 Arapeen Drive, Suite 202

Salt Lake City, Utah 84108

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (801) 994-7383

Former name or former address, if changed since last report: Not Applicable

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		LPCN		The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Explanatory Note

On August 3, 2026, Lipocine Inc. (the “Company”) reported the appointment of Michael Grissinger to the Company’s Board. This amendment is being filed to report Mr. Grissinger’s appointment to the Compensation Committee of the Board.

Item 5.02.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Offices

Appointment of Michael Grissinger to the Compensation Committee of the Board of Directors

On August 18, 2026, the Board of Directors (the “Board”) of the Company appointed Michael Grissinger to serve as a member of the Compensation Committee of the Board. Mr. Grissinger is eligible to receive an additional $7,500 per year for his service as a member of the Compensation Committee of the Board.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 21, 2026	LIPOCINE INC.

	By:	/s/ Mahesh V. Patel
	Name:	Mahesh V. Patel
	Title:	President and Chief Executive Officer

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

3 documents